Founded in 1998 as BioPort, Emergent Biosolutions is a biopharmaceutical company that develops what it refers to as "immunobiotics" - advanced vaccines produced using biotechnology. Currently, the Maryland-based company makes over 97% of its revenue from the sale of BioThrax, its FDA-approved Anthrax vaccine, to the U.S. government departments of Health and Human Services (HHS), as well as the Department of Defense (DoD).
Following the terrorist attacks of 911 and the subsequent anthrax scare, the U.S. government has made fighting bioterrosism a strong priority. In addition to purchasing Emergent's products, the government also funds some of its research aimed at developing new vaccines. Any shift in the government's stance would have a dramatic impact on Emergent's performance.(Read more at Wikinvest )